Skip to main content

Rituximab

Rituximab is a monoclonal antibody that was originally developed for the treatment of certain types of cancer in humans. In veterinary medicine, rituximab is increasingly being researched and used to treat similar cancers in dogs, particularly those affecting the lymphatic system.

Basics of Rituximab

Rituximab specifically targets the CD20 antigens on the surface of B cells. This makes it a valuable tool in the fight against B-cell related diseases, including certain forms of lymphoma.

Mechanism of action

  • Targeted therapy: Rituximab binds to the CD20 protein on B cells and leads to their destruction.
  • Oncology applications: Used in the treatment of B-cell lymphomas in dogs.

Fields of application

Although the primary use of rituximab is the treatment of lymphoma in humans, its use in dogs is beginning to address similar diseases.

Main applications

  • B-cell lymphomas: Rituximab is used in clinical trials and specialized veterinary clinics for the treatment of B-cell lymphomas in dogs.

Administration and dosage

The exact dosage and route of administration of rituximab must be carefully determined by a specialized veterinarian experienced in cancer therapies in dogs.

Dosage guidelines

  • Specialized treatment: Rituximab is typically administered intravenously and requires close monitoring during the infusion and afterwards.
  • Individualized therapy: The dose is tailored to the individual dog, depending on the type of lymphoma and overall health.

Side effects and monitoring

Like all medical treatments, rituximab can cause side effects that need to be monitored to ensure the safety and effectiveness of the therapy.

Common side effects

  • Infusion reactions: Symptoms may include fever, chills and nausea, similar to those seen in humans.
  • Immune system: Possible suppression of the immune system, which may increase the risk of infection.

Monitoring the treatment

  • Regular blood tests: Monitoring of blood levels to assess the impact on the immune system and other possible toxic effects.
  • Specialized aftercare: Close monitoring by the veterinarian, especially in the first hours after administration.

Rituximab is a promising approach in the treatment of B-cell lymphoma in dogs and represents an important transfer of human therapies to veterinary medicine. Close collaboration with specialized veterinarians and oncologists is necessary to achieve the best possible treatment results and to ensure your dog's safety during treatment.

The authors assume that a veterinarian should be consulted if an animal is ill and that medication should only be taken after consultation with a doctor or pharmacist. Only an individual examination can lead to a diagnosis and treatment decision.

We help you find the nearest vet → This way